Mechanism of Diacylglycerol-induced Membrane Targeting and Activation of Protein Kinase Cα*

Received for publication, March 22, 2004, and in revised form, April 16, 2004 Published, JBC Papers in Press, April 22, 2004, DOI 10.1074/jbc.M403191200

Robert V. Stahelin, Michelle A. Digman, Martina Medkova‡, Bharath Ananthanarayanan,
John D. Rafter, Heather R. Melowic, and Wonhwa Cho§

From the Department of Chemistry, University of Illinois, Chicago, Illinois 60607

The regulatory domains of novel protein kinases C (PKC) contain two C1 domains (C1A and C1B), which have been identified as the interaction site for sn-1,2-diacylglycerol (DAG) and phorbol ester, and a C2 domain that may be involved in interaction with lipids and/or proteins. Although recent reports have indicated that C1A and C1B domains of conventional PKCs play different roles in their DAG-mediated membrane binding and activation, the individual roles of C1A and C1B domains in the DAG-mediated activation of novel PKCs have not been fully understood. In this study, we determined the roles of C1A and C1B domains of PKCα by means of in vitro lipid binding analyses and cellular protein translocation measurements. Isothermal titration calorimetry and surface plasmon resonance measurements showed that isolated C1A and C1B domains of PKCα have opposite affinities for DAG and phorbol ester; i.e. the C1A domain with high affinity for DAG and the C1B domain with high affinity for phorbol ester. Furthermore, in vitro activity and membrane binding analyses of PKCα mutants showed that the C1A domain is critical for the DAG-induced membrane binding and activation of PKCα. The studies also indicated that an anionic residue, Glu177, in the C1A domain plays a key role in controlling the DAG accessibility of the conformationally restricted C1A domain in a phosphatidylserine-dependent manner. Cell studies with enhanced green fluorescent protein-tagged PKCα and mutants showed that because of its phosphatidylserine specificity PKCα preferentially translocated to the plasma membrane under the conditions in which DAG is randomly distributed among intracellular membranes of HEK293 cells. Collectively, these results provide new insight into the differential roles of C1 domains in the DAG-induced membrane activation of PKCα and the origin of its specific subcellular localization in response to DAG.

Protein kinase C (PKC)† are a family of serine/threonine kinases that mediate a wide variety of cellular processes (1, 2). Molecular cloning has identified more than 10 members of the PKC family. All PKCs contain an amino-terminal regulatory domain and a carboxyl-terminal catalytic domain. Based upon structural differences in the regulatory domain, PKCs are typically subdivided into three classes; conventional PKC (α, βI, βII, and γ subtypes), novel PKC (δ, ε, η, and ζ subtypes), and atypical PKC (ζ and η subtypes). PKCα is the first novel PKC isoform to be identified (3) and perhaps the most extensively studied one. PKCα is ubiquitously distributed among mammalian cells and tissues (4, 5), suggesting universal roles in mammals. Whereas PKCα has been generally implicated in cell growth inhibition (6–8) and apoptosis (9–11), it has been also shown to exert opposite effects in some cells (12). Recent gene disruption studies have also indicated that PKCα has cell type-specific functions, including negative regulation of proliferation of B cells (13), reduction in antigen-induced degranulation in mast cells (14), and homeostasis of smooth muscle cells (15). In some mammalian cells, PKCα has been reported to have opposing functions to another novel PKC, PKCε (7, 16–18). Understanding the molecular basis of these cellular functions of PKCα would require elucidation of the mechanism by which this novel PKC is specifically targeted to the membrane and activated.

It has been reported (19) that cellular PKCα activities are regulated by phosphorylation, proteolysis, sn-1,2-diacylglycerol (DAG), and other lipids. PKCs have three common phosphorylation sites in the activation loop, turn motif, and hydrophobic motif, respectively (20, 21). Phosphorylation on these sites by either upstream protein kinases (22, 23) or autophosphorylation (24) has been proposed to be essential for the full expression of enzyme activities. PKCα also has activation loop, turn, and hydrophobic motif sites at Thr505, Ser543, and Ser562 (25, 26), respectively, which are substantially phosphorylated in vivo. However, phosphorylation of Thr565 is not absolutely required for the PKCα activity but may be required for its stability (27). PKCα was also shown to be phosphorylated on several tyrosine residues in the H2O2-treated cells, which converts the enzyme into a constitutively active enzyme that is independent of DAG (25). In apoptotic cells, a catalytically active PKCα is generated by proteolysis, which then translocates to the nucleus (9–11, 28).

The mechanisms of PKC activation by DAG and its non-physiological analogs, phorbol esters, have been extensively...

* This work was supported by National Institutes of Health Grants GM52598, GM53987, and GM68849. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

‡ Present address: Dept. of Cell Biology, Yale University School of Medicine, P. O. Box 208002, 333 Cedar St., New Haven, CT 06520-8002.

§ To whom correspondence should be addressed: M/C 111, 845 West Taylor St., Chicago, IL 60607-7061. Tel.: 312-996-4883; Fax: 312-996-2183; E-mail: wcho@uic.edu.

† The abbreviations used are: PKC, protein kinase C; CHAPS, 3-[3-cholamidopropyl]dimethylammonio]-1-propanesulfonic acid; DAG, sn-1,2-diacylglycerol; OPG, 1-octanoyl-2-(8-pyrenyloctanoyl)-sn-3-glycerol; DiC8, sn-1,2-diocotoxy glycerol; DiC8, sn-1,2-dioleyxyglycerol; DMEM, Dulbecco’s modified Eagle’s medium; EGF, enhanced green fluorescent protein; HEK, human embryonic kidney; ITC, isothermal titration calorimetry; POPC, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; POPE, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine; POPS, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol; PIP2, 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-inositol; GM52598, GM53987, and GM68849. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

This paper is available on line at http://www.jbc.org
studied, with a particular emphasis on elucidating the roles of three membrane targeting domains (C1A, C1B, and C2) in the membrane translocation and activation of different PKC isoforms. The C1 domain (∼50 residues) is a cysteine-rich compact structure that was identified as the interaction site for DAG and phorbol ester (29–32), whereas the C2 domain (∼130 residues) is an 8-stranded β sandwich protein that is involved in Ca\(^{2+}\)-dependent membrane binding for conventional isoforms (33–36). As is the case with all novel PKCs, PKC\(\theta\) contains the amino-terminal non-Ca\(^{2+}\)-binding C2 domain, followed by a pseudosubstrate region, the C1A domain, and the C1B domain in the regulatory domain and the C3 and C4 domains in the catalytic domain. It has been reported that the two C1 domains of PKC\(\theta\) have disparate phorbol ester affinities and distinct roles in phorbol ester-induced PKC activation (37). Recent studies have revealed, however, that some PKC isoforms follow different mechanisms when they are activated by DAG and phorbol esters, respectively, because their C1A and C1B domains have opposite relative affinities for these ligands (38). This finding calls for the re-evaluation of the physiological relevance of previous mechanistic studies on the phorbol ester-induced activation of PKCs. To date, no systematic study on the mechanism of DAG-induced membrane binding and activation of novel PKC isoforms has been reported. On the basis of our recent mechanistic studies on conventional PKC isoforms, we undertook this study to elucidate how DAG induces the cellular membrane translocation and activation of PKC\(\theta\). In vitro membrane binding studies of individual membrane targeting domains (C1A, C1B, and C2) of PKC\(\theta\) and the full-length PKC\(\theta\) and mutants by isothermal titration calorimetry (ITC), surface plasmon resonance (SPR), and monolayer penetration analyses, as well as cellular membrane translocation measurements, reveal that PKC\(\theta\) has a unique membrane binding and activation mechanism, which derives from the distinct DAG affinities of the two C1 domains and the unique conformational properties of this novel PKC isoform.

**EXPERIMENTAL PROCEDURES**

**Materials**—1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE), 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphoglycerol (POPG), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoinositol (POPI), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoserine (POPS), cardiolipin, sn-1,2-dioleoylglycerol (DiC\(_2\)), and sn-1,2-dioleoylglycerol (DiC\(_4\)) were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL) and used without further purification. A fluorescent DAG analog, 1-2,3,5-tri-O-isopropyliden-sn-glycerol (ALdrich) as described elsewhere.\(^2\) Phorbol 12,13-dibutyrate (PDBu), phorbol 12-myristate 13-acetate, cholesterol, fatty acid-free bovine serum albumin, Triton X-100, ATP, octyl glucoside, and CHAPS were from Sigma. Phospholipid concentrations were determined by a modified Bartlett analysis (39). \(^{32}\)P-ATP (3 Ci/μmol) was from Amersham Biosciences. Restriction endonucleases and enzymes for molecular biology were obtained from New England Biolabs (Beverly, MA). Pioneer L1 sensor chip was from Bicaro AB (Piscataway, NJ). Dulbecco’s modiﬁed Eagle’s medium (DMEM) and LipofectAMINETM were from Invitrogen. Human embryonic kidney (HEK) 293 cell line, Zeocin, and ponasterone A were from Invitrogen.

**Expression Vector Construction and Mutagenesis**—Expression vectors for the C1A and C1B domains were constructed by subcloning the C1A and C1B domains sequences of rat PKC\(\theta\) into pEET21a vectors (Novagen, Madison, WI) between NcoI and XhoI sites by overlap extension polymerase chain reaction (40) using Pfu polymerase (Stratagene, La Jolla, CA). These vectors are designed to introduce a carboxyl-terminal His\(_6\) tag between the XhoI site and stop codon for affinity purification of expressed proteins. Baculovirus transfer vectors encoding the cDNA of PKC\(\theta\) with appropriate C1 domain mutations were generated by PCR (40) using pVL1392-PKC\(\theta\) plasmid as a template. Briefly, four primers, including two complementary oligonucleotides introducing a desired mutation and two additional oligonucleotides complementary to the 5′- and 3′-ends of the PKC\(\theta\) gene, respectively, were used for PCR mutagenesis. The 3′-end of the PKC\(\theta\) gene was modified using a 3′-end primer that was designed to mutate the stop codon and contain a His\(_6\) tag. Two DNA fragments overlapping at the mutation site were first generated and purified on an agarose gel. These two fragments were then annealed and extended to generate an entire PKC\(\theta\) gene containing a desired mutation, which was further amplified by PCR. The product was subsequently purified on an agarose gel, and PKC\(\theta\) was digested with NotI and EcoRI and subcloned into the pVL1392 plasmid digested with the same restriction enzymes. The mutation was verified by DNA sequencing.

Protein Expression and Purification—Escherichia coli strain BL21(DE3) (Novagen) was used as a host for C1 domain expression. The soluble C1B domain and the insoluble C1A domain were expressed and purified (38, 41). Full-length PKC\(\theta\) was expressed in baculovirus-infected SF9 cells. The transfection of SF9 cells with pVL1392-PKC\(\theta\) constructs was performed using a BaculoGoldTM transfection kit from BD Pharmingen. The plasmid DNA for transfection was prepared by using an EndoFree Plasmid Maxi kit (Qiagen) to avoid potential endotoxin contamination. Cells were incubated for 4 days at 27 °C, and the supernatant was collected and used to infect more cells for the amplification of virus. After three cycles of amplification, high-titer virus stock solution was obtained. SF9 cells were maintained as monolayer cultures in TMN-FH medium (Invitrogen) containing 10% fetal bovine serum (Invitrogen). For protein expression, cells were grown to 2 × 10\(^6\) cells/ml in 350-ml suspension cultures and infected with multiplicity of infection of 10. The cells were then incubated for 3 days at 27 °C. For harvesting, cells were centrifuged at 1,000 × g for 10 min, the pellet was washed once with sodium phosphate buffer, pH 8.0, and resuspended in 25 ml of extraction buffer containing 50 mM sodium phosphate, pH 8.0, 300 mM NaCl, 10 mM imidazole, 50 μg/ml leupeptin, 1% Triton X-100, and 0.2 mM phenylmethylsulfonyl fluoride. The suspension was homogenized in a hand-held homogenizer chilled on ice. The extract was centrifuged at 50,000 × g for 45 min at 4 °C. One ml of nickel-nitritrocitric acidagarose (Qiagen) was added to the supernatant and the mixture was incubated on ice while shaking at 80 rpm for 1 h. The mixture was poured onto a 10-ml column and the column was washed first with 20 mM HEPES buffer containing 50 mM sodium phosphate, pH 8.0, 15 mM imidazole, and subsequently with 15 ml of 50 mM sodium phosphate, pH 8.0, containing 300 mM NaCl and 15 mM imidazole. The column was washed with an additional 4 ml of the same buffer containing 20 mM imidazole. The protein was then eluted in 7 fractions of 0.5 ml of 50 mM sodium phosphate buffer containing 300 mM imidazole. Eluted fractions were then analyzed on a 10% sodium dodecyl sulfate-polyacrylamide gel. Fractions containing PKC\(\theta\) were concentrated and desalted in an Ultrafree-15 centrifugal filter device (Millipore). Protein concentration was determined by the bicinchoninic acid method (Pierce).

**Determination of PKC Activity**—Activity of PKC\(\theta\) was assayed by monitoring the initial rate of \(^{32}\)P-phosphate incorporation from \(^{32}\)P-ATP (50 μM, 0.6 μCi/tube) into myelin basic protein (200 μg/ml) or protamine sulfate (200 μg/ml) (both from Sigma). The reaction mixture contained large unilamellar vesicles (0.2 mM of total lipid concentration), 0.16 mM HCl, and 5 mM MgCl\(_2\) in 20 mM HEPES, pH 7.4. Because PKC\(\theta\) showed a high background activity toward the peptide substrate basic protein, this reaction was performed in the absence of ATP, which was only used for routine assays during purification. Reactions were started by adding 50 mM MgCl\(_2\) to the mixture and incubating for 5 (protamine sulfate) or 10 min (myelin basic protein) at room temperature, they were quenched by addition of 50 μl of 5% phosphoric acid. Seventy-five μl of quenched reaction mixtures were spotted on P-81 ion-exchange paper and eluted 4 times with 2 ml of solution of phosphoric acid followed by one wash in 95% ethanol. Papers were transferred into scintillation vials containing 4 ml of scintillation fluid (Fish) and radioactivity was measured by liquid scintillation counting.

**Monolayer Measurements**—Surface pressure (\(\pi\)) of solution in a-cir
cular Teflon trough (4 cm diameter × 1 cm deep) was measured using a Wilhelmy plate attached to a computer-controlled Cahn electronic balance (model C-32) as described previously (42). Five to 10 μl of phospholipid solution in ethanol/hexane (1:9 v/v) was spread onto 10 ml of subphase (20 mM Tris-HCl, pH 7.4, containing 0.16 μM KCl) to form a monolayer with a given initial surface pressure (π0). The subphase was continuously stirred at 60 rpm with a magnetic stir bar. Once the surface pressure reading of the monolayer had been stabilized (after about 5 min), the protein solution (typically 70 μl) was injected into the subphase through a small hole drilled at an angle through the wall of the trough and the change in surface pressure (Δπ) was measured as a function of time. Typically, the Δπ value reached a maximum after 30 min. It has been shown empirically that Δπ caused by a protein is maintained best when the two beams were placed at a 45° angle to the subphase through a small hole drilled at an angle through the wall of the trough (42). The maximal Δπ value at a given π0 depended on the protein concentration and reached a saturation value. Protein concentrations in the subphase were therefore maintained above such values to ensure that the observed Δπ represented a maximal value. The critical surface pressure (πc) was determined by extrapolating the Δπ versus π0 plot to the x axis (43).

**Surface Plasmon Resonance Analysis—Kinetics of vesicle-protein binding** was determined by the SPR analysis using a BIAcore X biosensor system (BIACORE AB). The lipid coating of the L1 chip has been described in detail previously (44–46). Before SPR measurement, the instrument was allowed to equilibrate with the buffer until the drift in signal was less than 0.3 resonance units/min. The sensor surface was then coated with lipid vesicles at a flow rate of 5 μl/min. The first flow cell was used as a control cell and was coated with 4500 resonance units of POPC. The second flow cell contained the surface coated with vesicles with varying lipid compositions (e.g. POPC/POPS/DiC14 = 59:40:1) at 4500 resonance units. After lipid coating, 30 μl of 50 mM NaOH was injected at 100 μl/min three times to stabilize the lipid layer. Typically, no further decrease in SPR signal was observed after one wash cycle. After coating, the drift in signal was allowed to stabilize below 0.3 resonance units/min before any binding measurements, which were performed at 23 °C and at a flow rate of 30 μl/min. Ninety μl of protein sample was injected for an association time of 3 min, whereas the dissociation was monitored for 10 min in running buffer. After each measurement, the lipid surface was typically regenerated with a 10-μl pulse of 50 mM NaOH. The regeneration solution was passed over the immobilized vesicle surface until the SPR signal reached the initial background value before protein injection. For data acquisition, 5 or more different concentrations (typically within a 10-fold range above or below the Kd) of each enzyme were used and data sets were repeated 3 or more times. When needed, the entire lipid surface was removed with a 5-min injection of 40 mM CHAPS followed by a 5-min injection of 40 mM octyl glucoside at 5 μl/min and the sensor chip was reloaded for the next set of measurements. All data was analyzed using BIACalculator (version 3.0 software (Biacore) to determine the rate constants of association (ka) and dissociation (kd) as described previously (44–46). Equilibrium dissociation constant (Kd) was either calculated from rate constants using an equation, Kd = ka/kd, assuming 1:1 binding, or directly determined from steady-state binding measurements as described previously (38). Mass transport was not a limiting factor in our experiments, as change in flow rate or ligand density did not affect kinetics of association and dissociation (47, 48).

**Isothermal Titration Calorimetry Measurements—Binding of C1 domain to water-soluble PDBu or DiC14 ligands** were measured using a MicroCal VP isothermal titration calorimeter (MicroCal Inc., Northampton, MA) (38). Protein samples used for the titration were prepared by dialyzing overnight against 4 litters of a working buffer (20 mM Tris-HCl, pH 7.4, containing 0.1 mg/ml Zeocin). MicroCal VP was protected at 30 °C using the working buffer as a reference and a dialuent. Protein and ligand concentrations used for each measurement varied according to the range of Kd value to be determined. Binding measurements were performed with 5-μl stepwise injections of the ligand into the protein in the sample cell. Injections were continued until saturating signals were observed. The collected data was analyzed with the Origin software (MicroCal) using a simple single-site model.

**Cell Culture**—A stable HEK293 cell line expressing the edosyne receptor (Invitrogen) was used for all experiments (49). Cells were cultured in DMEM supplemented with 10% fetal bovine serum at 37 °C in 5% CO2 and 98% humidity until 90% confluent. Cells were then passaged in the presence of a Lab-Tech TM chambered coverglass for later transfection and visualization. Only cells between the 5th and 20th passage were used. For transfection, 80–90% confluent cells in Lab-Tech TM-chambered coverglass wells were exposed to 150 μl of unsupplemented DMEM containing 0.5 μg of endotoxin-free DNA and 1 μl of LipofectAMINE reagent for 7–8 h at 37 °C. After exposure, the transfection medium was removed, the cells were washed once with fetal bovine serum-supplemented DMEM, and overlaid with fetal bovine serum-supplemented DMEM containing Zeocin and 5 μg/ml polybrene to induce protein production for 16–24 h.

**Microscopy**—Microscopy data were collected on a custom-built combination laser scanning confocal and multiphoton microscope. Briefly, a 150 MHz Ti:sapphire laser from multiphoton microscopy (Light Conversion, Milpitas, CA) was focused to a 1–2 μm depth. A custom fiber laser (Melles Griot, Carlsbad, CA) was selected using an acousto-optical tunable filter (NEOS, Melbourne, FL) and fiber launched into the scan head. Simultaneously, a 700-nm ultrashort, pulsed beam from a tunable Ti:sapphire laser set up for femtosecond operation (Qswitched, Mountain View, CA) was spatially filtered and launched into the scan head. The beam was then filtered through a neutral density filter reflecting 860 nm of light, directed toward the primary dichroic mirror (Chroma Technology, Brattleboro, VT), and then toward the YS scan mirrors (model 6350, Cambridge Technologies, Cambridge, MA). The light laser was focused using a Prairie Technologies (Middleton WI) scan lens, collimated by the ×1 Zeiss tube lens and directed toward a 40 × water corrected 1.2 numerical aperture Zeiss objective mounted on a Zeiss 200 m platform (Carl Zeiss Inc., Thornwood, NY). Light excited by the continuous wave 488 nm line was collected using a modified Prairie Technologies two-channel confocal detection apparatus equipped with Peltier-cooled 928p and 1477p style Hamamatsu photomultiplier tubes (Hamamatsu Corp. USA, Bridgewater, NJ). Light excited by the 700-nm ultrashort pulse was collected on a non-descanned pathway by Peltier-cooled 1477p style Hamamatsu photomultiplier tubes. All light was reflected and filtered using appropriate optics. Instrument control was accomplished using an ISS (Champaign, IL) 3-axis scanning card, ISS amplifiers, and two ISS 200 Khz analog lifetime cards. The software interface was SimFCS (Laboratory for Fluorescence Dynamics, University of Illinois, Urbana-Champaign, IL), a custom program written by Dr. Enrico Gratton and modified for control of this instrument. All experiments were carried out at the same laser power (found to induce minimal photobleaching over 30 scans) and the same gains and offset setting on the photomultiplier tubes. Transfected cells were washed twice with HEK buffer (1 mM HEPES, pH 7.4, containing 2.5 mM MgCl2, 140 mM NaCl, 5 mM KCl, and 6 mM sucrose). After washing, cells were overlaid with 150 μl of HEK buffer. Suitable cells were selected for imaging and a single image was taken for each cell before addition of OPG or DiC14. Then, the translocation of protein and subcellular localization of lipid was simultaneously monitored at fixed intervals (every 20 s) after 150 μl of HEK buffer containing 0.1 mg/ml OPG (or DiC14) was added. Control experiments were done with dimethyl sulfoxide (DMSO). Images were analyzed by calculating the integral of interest in the cytosol were defined, and the average intensity in a square (1 μm × 1 μm) obtained with respect to time. Membrane intensities were determined for each frame in individual cells by extending a line from the cytosol to the outside of the cell and reading off the intensity with distance along the line. By cross-checking, markers on the diagram with a table of intensity values corresponding to the place of interest in the cytosol. Intensity values converted to a ratio for each frame: membrane/cytosol. The values were then scaled for the entire time series from 0 to 100% of the obtained ratio for a given experiment. This allowed a comparison of ratiometric changes between experiments. Note that each experiment was repeated at least three times on a given day and was repeated at least two different days with different transfected cells.

**RESULTS**

**Phosphatidylserine (PS)-specific Membrane Binding and Activation of PKCα**—It has been long known that among different anionic phospholipids PS specifically enhances the membrane affinity and activity of PKCs (50, 51). Recently, however, it has been recognized that PS specificity can vary significantly among PKC isoforms depending on their structures and activation mechanisms. For instance, a conventional PKC, PKCy, and a novel PKC, PKCe, have been reported to show little PS specificity (38, 52). Previous reports have indicated that PS enhances the membrane affinity and activity of PKCδ (3, 53). To see whether this effect is induced specifically by PS or nonspecifically by other anionic phospholipids, such as phos-
phatidylylycerol (PG), we rigorously measured the PS specificity in membrane binding and activation of PKCβ.

We first measured the binding of PKCβ to POPC/POPS/DiC18 (59:40:1 in mole ratio) and POPC/POPG/DiC18 (59:40:1) vesicles by the SPR analysis, which has been shown to be a powerful tool for measuring membrane-protein interactions (43, 45, 54, 55). Representative sensorgrams are shown in Fig. 1. Although 40 mol % of POPS is higher than the physiological PS concentration, this lipid composition was employed in these studies to ensure that the binding of all PKCβ proteins, including some low affinity mutants, can be quantified under the same conditions. We also employed the lowest possible concentration of DiC18 (i.e. 1 mol %) that allows effective membrane binding of all PKCβ proteins to circumvent any membrane artifact caused by high DAG concentration. As listed in Table I, PKCβ exhibited a 5.5-fold higher affinity for POPC/POPS/DiC18 (59:40:1) vesicles than for POPC/POPG/DiC18 (59:40:1) vesicles, showing that PKCβ is selective for PS at least over PG in membrane binding. The higher affinity for PS-containing vesicles is attributed to a 1.7-fold increase in $K_d$ and a 3.2-fold decrease in $k_0$. It has been shown that membrane dissociation is slowed by short-range specific interactions or hydrophobic interactions achieved by the membrane penetration of protein (45, 56, 57). Thus it appears that the serine head group of PS interacts specifically with PKCβ or is able to facilitate membrane penetration of protein (or both). In this regard, PKCβ is more similar to a conventional PKC, PKCc, than to a novel PKC, PKCd (44, 52), despite the fact that PKCβ is a novel PKC with a non-Ca$^{2+}$-binding C2 domain.

To further investigate the effect of PS on the membrane penetration of PKCβ, we measured the interactions of PKCβ with various lipid monolayers (43). In this study, we monitored $\Delta \pi$ caused by the penetration of PKCβ to POPC/POPS and POPC/POPG mixed monolayers with varying surface packing density (i.e. different $p_0$). The resulting $\Delta \pi$ versus $p_0$ plots (Fig. 2) show that PKCβ is able to penetrate PS-containing monolayers more effectively than PG-containing monolayers. This indicates that PS can specifically induce the membrane penetration of PKCβ, as was the case with PKCc (52). When compared with PKCc, however, PKCβ required a higher POPS concentration to exhibit comparable monolayer penetration; i.e. >40 mol % of POPS was needed for PKCβ to penetrate the monolayer with $p_0 > 30$ dyne/cm and to fully express PS selectivity, whereas PKCc was able to penetrate the POPC/POPS (70:30) monolayer with $p_0 > 30$ dyne/cm (52). Thus, PKCβ is similar to PKCc in that PS can specifically induce its membrane penetration but is different from PKCc in that a significantly higher concentration of PS is required for PKCβ to penetrate the densely packed membrane. It was reported that DAG does not affect the monolayer penetration per se of PKCc, although greatly enhancing its membrane affinity (52, 58). Similarly, DiC18 did not directly affect the penetration of PKCβ into the POPC/POPS (50:50) monolayer (data not shown).

We also measured the kinase activity of PKCβ in the presence of PS- and PG-containing vesicles, i.e. POPC/POPS/G1/ DiC18 (99:1:x:1). Fig. 3 clearly shows that PKCβ is activated much more readily by PS-containing vesicles than by PG-containing vesicles; the maximal activity achieved with PG-containing vesicles reaches only 20% of that achieved with PS-containing vesicles. Again, this behavior is similar to that of PKCc, but is in sharp contrast to that of PKCe, which is activated equally well by PS- and PG-containing vesicles (52). Collectively, these results indicate that membrane binding affinity and activity of PKCβ are selectively enhanced by PS.

**Role of C2 Domain in Membrane Binding and Activation of PKCβ**—It has been well established that the C2 domains of conventional PKCs are involved in the Ca$^{2+}$-dependent membrane binding and activation of these PKCs (33, 59, 60). However, the role of non-Ca$^{2+}$-binding C2 domains of novel PKCs remains unclear. Recent studies have indicated that the C2 domain of PKCe may be involved in membrane binding. For instance, Ochoa et al. (61) reported that the C2 domain of PKCe could interact nonspecifically with anionic phospholipids, whereas Pepio et al. (62) reported that phosphorylation of Ser36 in the C2 domain of PKC Aplysia II, which is more closely related to mammalian PKCe than to PKCβ, promoted the membrane interaction of the C2 domain. The C2 domain of PKCβ shares only 16% homology with that of PKCe and major differences are found in their tertiary structures, particularly in the loop regions (61, 63, 64). To see if the C2 domain plays any role in the membrane binding of PKCβ, we measured the membrane binding properties of isolated C2 domain of PKCβ and also...
membrane binding and activation of full-length PKC. The isolated C2 domain of PKCα (with up to 50 μM protein) exhibited no detectable binding to POPC/POPS, POPC/POPG, or POPC/POPA mixed vesicles containing up to 50% anionic phospholipids in the SPR analysis. Furthermore, the C2 deletion had only small effects on the vesicle binding (Table I) or activation (Fig. 3) of the full-length protein, indicating that this C2 domain does not play a direct role in the DAG-dependent membrane binding and activation of PKCα.

**Differential DAG Affinity of C1A and C1B Domains**—Our previous studies indicated that the C1A domain plays a critical role in the DAG-induced membrane binding and activation of PKCα (38, 65), whereas both the C1A and C1B domains of PKCγ participate in these processes (38). This is ascribed to the fact that the C1A domain of PKCα has higher DAG affinity, whereas both the C1A and C1B domains of PKCγ have comparable DAG affinity and conformational flexibility. Roles of the C1A and C1B domains in the phorbol ester-induced activation of novel PKCs have been extensively studied (37, 66–71). The affinity of isolated C1A and C1B domains of novel PKCs for phorbol esters has also been measured (72, 73). However, no systematic study has been reported on the physiologically more relevant DAG-induced activation of novel PKCs. Because it was shown that the principles learned from the phorbol ester-mediated activation of a PKC isoform may not be applied to the DAG-mediated activation of the PKC (38), it is necessary to measure the relative DAG affinity of the C1A and C1B domains and their relative contribution to DAG-induced novel PKC activation to fully understand the mechanism of DAG-induced activation of novel PKC.

To achieve this goal, we first expressed the isolated C1 and C2 domains of PKCα. The C1B domain was expressed as soluble protein in E. coli, whereas the C1A domain was expressed as inclusion bodies, which were then solubilized in urea and refolded. To verify that the C1A and C1B domains of PKCα...
were correctly folded, their affinity for PDBu was measured by ITC. The values of $K_d$ and stoichiometry for C1-PDBu binding are summarized in Table II. The C1A domain had no detectable affinity for PDBu, whereas the C1B domain bound PDBu with a $K_d$ of 58 nM. This value is higher than the reported $K_d$ for the C1B domain because the latter value was determined in the presence of PS vesicles (73).

We then determined by ITC analysis the affinity of the C1A and C1B domains for a short-chain DAG analog, DiC$_8$, which was shown to exist as a monomer in the concentration range (10–100 nM) used for this binding study (38). As shown in Table III, the C1A domain bound DiC$_8$ with a $K_d$ of 85 nM, whereas the C1B domain showed no detectable binding. Thus, as was the case with PKCa (38, 74), the C1A and C1B domains of PKC$_8$ have opposite affinities for DAG and phorbol ester, i.e. the C1A domain with high affinity for DAG and the C1B domain with high affinity for phorbol ester. We also measured the binding of C1A and C1B domains to DAG and phorbol ester with longer acyl chains that are incorporated in the lipid bilayer. First, the affinity of C1 domains was measured for POPC/POPS/DiC$_{18}$ vesicles by SPR analysis. The C1B domain exhibited lower affinity for the DiC$_{18}$-containing POPC/POPS/DiC$_{18}$ (67.5:30:2.5) vesicles by SPR analysis. The binding of C1A and C1B domains to DAG and phorbol ester is consistent with the putative involvement of the mutated hydrophobic residues in membrane penetration (45, 56, 57).

**Table II**

| Proteins | PDBu, literature$^a$, $K_d$ | PDBu, ITC analysis | PMA$^b$, SPR analysis, $K_d$ |
|----------|--------------------------|-------------------|--------------------------|
| PKC$_8$-C1A | $\sim$300 | NM$^c$ | NM $\pm$ 360 $\pm$ 21 |
| PKC$_8$-C1B | 1.0 $\pm$ 0.1 | 0.96 $\pm$ 0.01 | 58 $\pm$ 26 $\pm$ 4 |

$^a$ Taken from Ref. 73.

$^b$ POPC/POPS/phorbol 12-myristate 13-acetate (69.95:30:0.05) vesicles.

$^c$ NM, not measurable.

**Differential Roles of C1A and C1B Domains in PKC$_8$ Activation**—To test the notion that the C1A domain plays a major role in DAG-mediated membrane binding and activation of PKC$_8$, we measured the effects of selected mutations of the C1A and C1B domains of PKC$_8$ on its membrane binding and activation. Mutations were made on hydrophobic residues whose counterparts in conventional PKCs have been shown to be important for their membrane binding (38, 65); i.e. W180G and L182G for the C1A domain and W252G and L254G for the C1B domain. First, the activity measurements of these mutants in the presence of POPC/POPS/DiC$_{18}$ (99:x:1) vesicles showed that the C1A domain mutants, W180G and L182G, had much lower activity than wild type and C1B domain mutants, W252G and L254G (Fig. 4). In accordance with this, W180G and L182G had 9- and 6-fold lower affinity for POPC/POPS/DiC$_{18}$ vesicles than wild type, respectively, whereas W252G and L254G had wild-type-like affinity (see Table I). Both W180G and L182G exhibited an increase in $k_d$, which is consistent with the putative involvement of the mutated hydrophobic residues in membrane penetration (45, 56, 57). Monolayer measurements further supported this notion. The C1A domain mutations greatly reduced monolayer penetration, whereas the C1B domain mutation (W252G) had a smaller effect (see Fig. 5). Interestingly, the C1A domain mutants had much reduced activity even under the condition where they were expected to be fully vesicle-bound (i.e. with 0.2 mM of POPC/POPS/DiC$_{18}$ vesicles containing $>$40 mol % PS; see Fig. 4), suggesting that the membrane penetration and correct positioning of the C1A domain is important not only for membrane binding but also for optimal PKC$_8$ activation.

**Origin of PS Specificity**—We previously showed that Asp$^{55}$ in the C1A domain of PKCs is involved in tethering of the C1A domain to the other part of the PKC molecule (44). It was postulated that the PS specificity of PKCo activation derives from the release of the tethering by PS that binds to the C2 domain (and possibly other parts) of PKCo (44). PKCo has Glu$^{177}$ in place of Asp$^{55}$ of PKCa but its C2 domain shows no affinity for PS (see Table I), suggesting that PKCo might achieve PS specificity by a different mechanism. To test this notion, we replaced Glu$^{177}$ in the C1A domain and its counterpart in the C1B domain, Asp$^{245}$, by Ala and measured vesicle binding, monolayer penetration, and kinase activity of mutants.

SPR vesicle binding measurements showed that E177A and D245A bound to POPC/POPS/DiC$_{18}$ (59:40:1) vesicles 12- and 2.6-fold, respectively, more strongly than wild type (see Table III).
I). Importantly, both E177A and D245A showed even more greatly enhanced affinity for POPC/POPG/DiC18 (59:40:1) vesicles. As a result, both mutants exhibited much reduced PS selectivity; i.e. E177A showed only 2.1-fold preference for PS-containing vesicles, and D245A actually had slightly higher affinity for PG-containing vesicles. Interestingly, both mutations not only increase $k_a$ but also decrease $k_d$ in vesicle binding to both PS- and PG-containing vesicles. Thus, the mutations did not simply enhance nonspecific electrostatic binding to anionic vesicles by removing an anionic residue. It is more likely that the mutations facilitate membrane penetration of PKC\textsubscript{δ} by unleashing its C1 domains. To test this notion, we measured the penetration of E177A and D245A into POPC/POPS (7:3) and POPC/POPG (7:3) monolayers. As shown in Fig. 6, both E177A and D245A were able to penetrate the POPC/POPS (7:3) and POPC/POPG (7:3) monolayers more effectively than wild type.

We also measured the activity of wild type and mutants as a function of anionic lipid composition in POPC/POPS(G)/DiC18 (99-x:x:1) vesicles. As shown in Fig. 7, both E177A and D245A showed higher activity than wild type at any given POPS (or POPG) concentration. Also, E177A and D245A, E177A in particular, only modestly (i.e. <2-fold) favored POPS over POPG, whereas the wild type showed high PS selectivity in the whole range of anionic phospholipid concentration used in these measurements. Thus, it appears that both Glu\textsubscript{177} in the C1A domain and Asp\textsubscript{245} in the C1B domain are involved in PS specificity in both membrane binding and activation of PKC\textsubscript{δ}.

Cellular Membrane Translocation—To understand how in \textit{vitro} DAG-dependent membrane binding properties of PKC\textsubscript{δ} affects its cellular membrane targeting, we monitored the DAG-dependent subcellular translocation of PKC\textsubscript{δ} and selected mutants, each tagged with EGFP, in HEK293 cells. Control SPR experiments showed that PKC\textsubscript{δ} with the EGFP tag at the carboxyl terminus had the affinity for POPC/POPG/DiC\textsubscript{18} (59:40:1) vesicles that was comparable with their non-EGFP-tagged counterparts employed in \textit{vitro} studies (see Fig. 1). Furthermore, the cellular level of expression of different protein constructs was comparable in most cells when assessed by Western blotting using PKC\textsubscript{δ}-specific antibodies (data not shown). Finally, a visual inspection did not show obvious signs of apoptosis, such as rounding of cells and bleb formation, in any HEK293 cells expressing PKC\textsubscript{δ} and mutants under our experimental conditions.

Membrane translocation of EGFP-tagged PKC\textsubscript{δ} and mutants was induced by treating transfected HEK293 cells with 0.1 mg/ml short-chain DAGs, OPG, or DiC\textsubscript{18}, because they are much more readily distributed to intracellular membranes than DiC\textsubscript{18}. In particular, fluorogenic OPG allowed us to monitor the time lapse location of DAG and PKC\textsubscript{δ} simultaneously. This is important because the cellular spatiotemporal dynamics of...
PKCδ would follow that of DAG. For monitoring OPG, two-photon excitation was essential for exciting and circumventing the photobleaching of the pyrene probe. Fig. 8 shows the time lapse images of OPG and EGFP-tagged proteins in representative cells. A minimum of quadruple measurements were performed for each protein with 5 cells monitored for each measurement. Typically, >80% of the cell population showed similar behaviors with respect to DAG-induced PKCδ translocation. Because its lipophilicity is lower than that of natural DAGs with longer acyl chains, OPG was rapidly distributed to all cellular membranes within 30 s when added to the cells (Fig. 8A). Interestingly, wild type PKCδ translocated exclusively to the plasma membrane even when OPG was found in other intracellular membranes (Fig. 8B). Quantitative evaluation of the cellular distribution of EGFP intensity throughout the cell (see Fig. 9A) demonstrates the predominant EGFP population at the plasma membrane. These results suggest that the PS specificity of PKCδ might govern its specific targeting to the PS-rich plasma membrane. This notion is further supported by the dual subcellular localization pattern of E177A and D245A, which have much more reduced PS specificity than wild type. Cell images (Fig. 8, B and C) and fluorescence intensity profiles (Fig. 9, B and C) indicate that significant portions of these mutants are localized to the nuclear membrane. Similar results were obtained when HEK293 cells were activated by DiC8 in lieu of OPG (data not shown).
We previously showed that many cellular proteins exhibiting specific targeting to the plasma membrane have pronounced specificity for the vesicles whose lipid head group composition recapitulates that of the cytoplasmic leaflet of plasma membrane over vesicles with the lipid compositions of other intracellular membranes, such as nuclear membrane (49). To see if differential subcellular targeting behaviors of PKCε and the two mutants truly reflect their lipid head group specificity, we measured their binding to vesicle mimics of the plasma membrane and nuclear membrane (49) containing 1 mol % DiC₁₈ by the SPR analysis. These mimics are designed to recapitulate the lipid head group compositions, but not the acyl group compositions, of cell membranes. As listed in Table IV, PKCε binds the plasma membrane mimic 50-fold more strongly than the nuclear membrane mimic. Interestingly, E177A and D245A exhibited significantly reduced specificity for the plasma membrane mimic when compared with the wild type. In agreement with the loss of PS specificity data, E177A binds only 6-fold more strongly to the plasma membrane mimic than the nuclear membrane mimic, whereas D245A exhibits a similar loss of specificity for the plasma membrane with 6-fold higher affinity for the plasma membrane mimic compared with the nuclear membrane mimic. These binding measurements support the notion that the differential subcellular distribution of PKCε and mutants derives at least in part from their different lipid head group specificity.

We also determined the rates of OPG (or DiC₁₈)-induced plasma membrane translocation for wild type and mutants to evaluate the correlation between their in vitro vesicle affinity and cellular membrane translocation efficiency. Good correlation has been observed between the in vitro vesicle affinity of membrane targeting domains and their cellular membrane translocation rates (49). The analysis of EGFP intensity versus time plots showed that E177A and D245A had significantly faster rates of translocation to the plasma membrane than wild type (see Fig. 8E), respectively, which is in accordance with their higher affinity for the plasma membrane mimic than wild type. This also supports the notion that both E177A and D245A are less conformationally restricted than wild type and thus can bind DAG-containing membranes more readily. Fig. 8E seems to indicate that E177A and D245A have essentially the same degrees of plasma membrane translocation as wild type despite their higher membrane affinity. It should be noted, however, that they show dual targeting to plasma and nuclear membranes and that the total extent of membrane translocation for these mutants are significantly higher than that of wild type. We also found that the C1B hydrophobic site mutants (W252G and L254G) behaved like wild type, whereas C1A domain mutants (W180G and W182G) translocated significantly more slowly and less extensively to the plasma membrane than wild type (see Fig. 8E), which is again consistent with our in vitro membrane binding data. Thus, it would seem that the C1A domain plays the same major role in both in vitro and cellular DAG-mediated membrane translocation of PKCε.

Last, we measured the effects on PKCε translocation of an actin polymerization inhibitor (cytochalasin D) and a microtubule depolymerizing compound (colcemide) to see if the interaction of PKCε with cytoskeletal proteins is important for its specific plasma membrane targeting as proposed previously (75). Under our experimental conditions, pretreatment of HEK293 cells for 1 h with neither cytochalasin D (up to 1 μM) nor colcemide (up to 0.5 μM) had any detectable effect on the subcellular localization of PKCε and mutants (see Fig. 8F).

**DISCUSSION**

The present study illustrates how three membrane targeting domains (C1A, C1B, and C2 domains) of PKCε mediate its membrane binding and activation in response to DAG. Our characterization of the isolated C2 domain of PKCε and the C2 deletion mutant indicate that the C2 domain is not directly involved in either membrane binding or enzyme activation. It is still possible, however, that the C2 domain serves as a protein-protein interaction site in the cell, as previously proposed (75, 76). The isolated C1A domain of PKCε has much higher DAG affinity than the C1B domain, and thus under physiologically relevant conditions only the C1A domain is expected to bind DAG. In accordance with this notion, mutations of hydrophobic residues in the C1A domain greatly reduced the affinity of PKCε for DAG-containing vesicles and its enzyme activity in the presence of DAG-containing vesicles, whereas corresponding mutations in the C1B had much smaller effects. In particular, a C1A domain mutant, W180G, has only 20% of wild type activity even with high PS concentrations in vesicles. Our monolayer penetration data, in conjunction with the SPR vesicle binding data showing that the C1A domain hydrophobic site mutations reduce the vesicle affinity of PKCε mainly by kₐ, indicate that membrane penetration of the C1A domain is an essential step in its function in membrane binding and activation of PKCε. Our measurements also showed that the C1B domain of PKCε has higher affinity for phorbol esters than the C1A domain, which is consistent with previous reports showing the importance of the C1B domain in phorbol ester-induced membrane targeting and activation of PKCε (67). Therefore, these data represent another example demonstrating disparate mechanisms for DAG- and phorbol ester-induced PKC activation (38).

As is the case with PKCa, PKCε exhibits definite PS selectivity in vesicle binding and kinase activity. Our previous study on PKCa (44) indicated that Asp⁵⁶ of the C1A domain of PKCa
is involved in tethering of the C1A domain to the PKC molecule and that this tethering is released specifically by PS, hence the PS specificity. The mutation of Asp55 of PKCα to Ala, which releases the tether, significantly enhances the *in vitro* and cellular membrane affinity and activity of PKCα and dramatically lowers its PS selectivity. For PKCγ with no PS selectivity and specificity, however, the mutation of its C1A domain anionic residue that corresponds to Asp55 of PKCα had no effect on the DAG-induced membrane binding and activation of PKCγ (38). The present study shows that the mutation of Glu177, which corresponds to Asp55 of PKCα, to Ala dramatically improves membrane affinity, activation, and monolayer penetration capability of PKCγ and greatly reduces PS selectivity. Therefore, it would seem that PS specifically disrupts the Glu177-mediated C1A domain tethering and thereby induces membrane penetration and activation of PKCγ.

For PKCα, the mutation of Asp116 in the C1B domain had minor effects on its vesicle and enzyme activity under specific conditions, *i.e.* in the presence of PS- and DAG-containing vesicles, but significantly enhanced the enzyme activity under nonspecific conditions, *e.g.* in the presence of PG-containing vesicles or at lower calcium concentrations (44). This suggested that the residue might play a role in restricting the mobility of the C1B domain and thereby suppressing nonspecific activation, although it is not directly involved in enzyme activation or PS specificity (44). In contrast, the mutation of Asp116 of PKCγ had no detectable effect, because of the conformationally free nature of the C1 domains in PKCγ (38). Our mutational analysis indicates that Asp116 of the C1B domain of PKCγ might be more directly involved in enzyme activation and PS specificity than Asp116 of PKCα. D245A of PKCγ has 2.6-fold higher affinity for POPC/POPE/POPS/DiC18 (59:40:1) vesicles than wild type (Table I), has about 2-fold higher activity than wild type in the presence of PS-containing vesicles (Fig. 7), penetrates the PS-containing lipid monolayer more efficiently than wild type (Fig. 6), and shows little PS selectivity in vesicle binding and enzymatic action (Table I and Fig. 7). Because the mutations of hydrophobic residues in the C1B domain of PKCγ had essentially no effect on both the *in vitro* and cellular membrane affinity and activity of PKCγ, it is not likely that the role of Asp245 is to tether the C1B domain, as proposed for Asp116 of the C1A domain. More likely, it would influence the tethering of the C1A domain to the PKC molecule, directly or indirectly. Although further studies are needed to address this issue, one can speculate that the difference between PKCα and PKCγ in terms of the role of the anionic residue in the C1B domain (Asp116 of PKCα and Asp245 of PKCγ) might derive from the different structural arrangements of C1 and C2 domains and the different properties of their C2 domains. For example, the C2 domain of PKCα has been shown to specifically bind PS (49, 77) and plays a key role in the Ca2+-dependent membrane binding of protein (33, 59, 60), whereas that of PKCδ seems to play a direct role in neither PS (or membrane) binding nor PS specificity (see Table I). These differences might also explain why PKCδ requires a higher PS concentration than PKCα for the membrane binding, monolayer penetration, and activation.

Our recent studies on various membrane targeting domains and proteins have shown that the lipid head group specificity and membrane affinity of these proteins govern the destination and efficiency of their subcellular membrane targeting, respectively (33, 49, 78, 79). Specifically, it has been demonstrated that proteins with PS specificity, including the C2 domain of PKCα, are either pre-localized or targeted to the PS-rich cytoplasmic leaflet of the plasma membrane (49). Not taking into account the potential protein-protein interactions (75, 76), PKCδ is expected to translocate to any cell membranes containing DAG, if its membrane targeting is solely driven by C1A-DAG interactions. However, our *in vitro* binding study using cell membrane-mimicking vesicles and our membrane translocation study in HEK293 cells show that the PS specificity of PKCδ plays a decisive role in its subcellular localization. PKCδ preferentially translocates to the plasma membrane when DAG is randomly distributed among cell membranes. More important, this specific targeting can be significantly disrupted by reducing its PS specificity, as seen for E177A and D245A. In conjunction with the good semiquantitative correlation between the *in vitro* membrane affinity of PKCδ mutants and the rate and extent of their cellular membrane translocation (Fig. 8E), this also suggests that membrane-protein interactions play a major role in the cellular membrane targeting of PKCδ, at least in HEK293 cells under our experimental conditions. This notion is further supported by the finding that the disruption of cytoskeletal proteins in HEK293 cells did not have any detectable effect on the membrane translocation of PKCδ.

Apparently, our results are at odds with recent reports indicating that PKCδ is specifically targeted to the mitochondria (80, 81) and the nucleus (9–11, 28). It should be noted that these studies were performed under different conditions and typically on longer time scales (i.e. >1 h incubation). Under our experimental conditions (*i.e.* OPG or DiC6 activation for <30 min), PKCδ did not induce apoptosis in HEK293 cells and shows no detectable translocation to the mitochondria and the nucleus. However, it should be noted that the C1A domain of PKCδ, as with other C1 domains, would sensitively monitor the spatiotemporal dynamics of DAG and that PKCδ would specifically translocate to the mitochondria if DAG is generated.

### Table IV

**Affinity of PKCδ and mutants for cell membrane mimics determined from SPR analysis**

| Proteins | k<sub>d</sub> | k<sub>d</sub> | K<sub>d</sub> | PM specificity<sup>a</sup> |
|----------|---------------|---------------|--------------|--------------------------|
|          | s<sup>–1</sup> | s<sup>–1</sup> |              |                          |
|          |             |             |              |                          |
| PKCδ     | (3.4 ± 0.5) × 10<sup>6</sup> | (8.0 ± 0.7) × 10<sup>3</sup> | (2.4 ± 0.4) × 10<sup>9</sup> |                          |
| E177A    | (1.1 ± 0.3) × 10<sup>7</sup> | (1.2 ± 0.3) × 10<sup>3</sup> | (1.1 ± 0.4) × 10<sup>10</sup> |                          |
| D245A    | (5.5 ± 0.5) × 10<sup>6</sup> | (1.5 ± 0.2) × 10<sup>3</sup> | (2.7 ± 0.4) × 10<sup>10</sup> |                          |
| PKCδ     | (3.8 ± 0.6) × 10<sup>6</sup> | (4.5 ± 0.3) × 10<sup>2</sup> | (1.2 ± 0.2) × 10<sup>7</sup> | 50                       |
| E177A    | (5.9 ± 0.5) × 10<sup>6</sup> | (4.3 ± 0.6) × 10<sup>3</sup> | (7.0 ± 1.1) × 10<sup>10</sup> | 6                        |
| D245A    | (3.8 ± 0.4) × 10<sup>6</sup> | (5.5 ± 0.7) × 10<sup>3</sup> | (1.5 ± 0.2) × 10<sup>9</sup> | 6                        |

<sup>a</sup> Ratio of (1/K<sub>d</sub>) for the plasma membrane mimic to (1/K<sub>d</sub>) for the nuclear membrane mimic.
mainly at the outer mitochondrial membrane under certain physiological conditions. It is also possible that PKCδ is targeted to other organelles via its initial plasma membrane localization, as reported for other proteins (82).

Opposing cellular actions of two novel PKCs, PKCδ and PKCe, have been reported under different conditions (7, 16–18). Although specific cellular adaptor proteins that mediate differential membrane localization and activities of the two PKCs have been reported (16, 75, 83, 84), our present study implies that distinct membrane binding and activation mechanisms of these PKCs might also contribute to their differential cellular actions. Our previous study showed that PKCe has low PS specificity and has generally lower affinity than PKCα for any anionic vesicles (e.g. POPC/POPS/DiC1(6), 60:30:1) (52). Our preliminary study3 also indicates that neither C1A nor C1B domains of PKCs are conformationally restricted, as it is the case with PKCy (38). PKCe is similar to PKCδ in that both have low affinity for PS-containing vesicles and lower penetration into PS-containing monolayers than PKCα, presumably because of the lack of Ca2+- and membrane-binding C2 domains. Unlike PKCe, however, PKCδ displays clear PS specificity, which should differentially affect their membrane targeting and activation in the cell.

In summary, this study illustrates the mechanism by which a novel PKC, PKCδ, binds model cell membrane and gets activated in response to DAG. The study provides another example of how structural differences among PKC isoforms cause the differences in membrane binding and activation mechanisms. It also underscores the fact that many PKC isoforms are activated by different mechanisms when activated by DAG and phorbol esters, respectively. The PS specificity of PKCe, which is likely to derive from the specific unlocking of the tethered C1A domain by PS, causes this PKC to translocate preferentially to the PS-rich plasma membrane, thereby allowing its specific activation in the plasma membrane under certain physiological conditions. In conjunction with our previous mechanistic studies on conventional PKCs, this study provides a basis for further investigation of the molecular mechanisms underlying the subcellular targeting and activation of other novel PKC isoforms.

REFERENCES

1. Newton, A. C. (2001) Chem. Rev. 101, 2533–2564
2. Newton, A. C. (2003) Methods Mol. Biol. 233, 3–7
3. Ono, Y., Fujii, T., Ogita, K., Kikuchi, K., Igarashi, K., and Nishizuka, Y. (1988) J. Biol. Chem. 263, 6927–6932
4. Leibersperger, H., Schewendt, M., Gernold, M., and Marks, F. (1991) J. Biol. Chem. 266, 14775–14784
5. Wetsel, W. C., Khan, A. M., Merchantehl, I., Rivera, H., Halpern, A. E., Phung, H. M., Negro-Vilar, A., and Hannun, Y. A. (1992) J. Cell Biol. 117, 121–128
6. Fukumoto, S., Nishizawa, Y., Hosoi, M., Kaya, H., Yamakawa, K., Ohno, S., and Morii, H. (1997) J. Biol. Chem. 272, 13816–13822
7. Mischak, H., Godinheit, J. A., Kolch, W., Martiny-Baron, G., Schaechtle, C., Kazanietz, M. G., Blumberg, P. M., Pierre, J. H., and Mushinski, J. F. (1993) J. Biol. Chem. 268, 6090–6096
8. Watanabe, T., Ono, Y., Taniyama, Y., Hazama, K., Igarashi, K., Ogita, K., Kikukawa, U., and Nishizuka, Y. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 10159–10163
9. Emoto, Y., Manome, Y., Meinhardt, G., Kikushi, K., Kharbanda, S., Robertson, M., Ghayur, T., Wong, W. K., Kamen, R., and Weiss, R. (1995) EMBO J. 14, 6148–6156
10. Ghayur, T., Hugunin, M., Talanian, R. V., Washko, S., Quinlan, C., Emoto, Y., Pandey, P., Datta, R., Huang, Y., Kharbanda, S., Allen, H., Kamen, R., Wong, W., and Kufe, D. (1996) J. Exp. Med. 184, 2393–2404
11. Mizuno, K., Koda, K., Araki, T., Imaoka, T., Kobayashi, Y., Akita, Y., Shimomura, M., Kishi, S., and Ohno, S. (1997) Eur. J. Biochem. 250, 7–18
12. Wang, Q. J., Aso, P., Goodwin, D., Blumberg, P. M., Mischak, H., and Mushinski, J. F. (1997) J. Biol. Chem. 272, 76–82
13. Miyamoto, A., Nakayama, K., Imaki, H., Hirase, S., Jiang, Y., Abe, M., Tsukiyama, T., Nagahama, H., Ohno, S., Hatakeyama, S., and Nakayama, K. I. (2002) Nature 416, 865–869
14. Leitges, M., Gimborg, K., Ellis, W., Kalesnikoff, J., Hughes, M. R., Krystal, G., and Huber, M. (2002) Mol. Cell. Biol. 22, 3970–3980

R. V. Stahelin and W. Cho, manuscript in preparation.
74. Slater, S. J., Ho, C., Kelly, M. B., Larkin, J. D., Taddeo, F. J., Yeager, M. D., and Stubbs, C. D. (1996) J. Biol. Chem. 271, 4627–4631
75. Lopez-Lluch, G., Bird, M. M., Canas, B., Godovac-Zimmerman, J., Ridley, A., Segal, A. W., and Dekker, L. V. (2001) Biochem. J. 357, 39–47
76. Song, J. S., Swann, P. G., Szallasi, Z., Blank, U., Blumberg, P. M., and Rivera, J. (1998) Oncogene 16, 3357–3368
77. Verdaguer, N., Corbalan-Garcia, S., Ochoa, W. F., Fita, I., and Gomez-Fernandez, J. C. (1999) EMBO J. 18, 6329–6338
78. Ananthanarayanan, B., Das, S., Rhee, S. G., Murray, D., and Cho, W. (2002) J. Biol. Chem. 277, 3568–3573
79. Kulkarni, S., Das, S., Funk, C. D., Murray, D., and Cho, W. (2002) J. Biol. Chem. 277, 13167–13174
80. Majumder, P. K., Pandey, P., Sun, X., Chenn, K., Datta, R., Saxena, S., Kharbanda, S., and Kufe, D. (2000) J. Biol. Chem. 275, 21793–21796
81. Caruso, M., Maitan, M. A., Rifulco, G., Miele, C., Vigliotta, G., Orisente, F., Formisano, P., and Beguinot, F. (2001) J. Biol. Chem. 276, 45088–45097
82. Matthews, S. A., Iglesias, T., Rozengurt, E., and Cantrell, D. (2000) EMBO J. 19, 2935–2945
83. Mochly-Rosen, D., Henrich, C. J., Cheever, L., Khaner, H., and Simpson, P. C. (1990) Cell Regul. 1, 693–706
84. Mochly-Rosen, D., and Gordon, A. S. (1998) FASEB J. 12, 35–42
Mechanism of Diacylglycerol-induced Membrane Targeting and Activation of Protein Kinase C δ
Robert V. Stahelin, Michelle A. Digman, Martina Medkova, Bharath Ananthanarayanan, John D. Rafter, Heather R. Melowic and Wonhwa Cho

J. Biol. Chem. 2004, 279:29501-29512. doi: 10.1074/jbc.M403191200 originally published online April 22, 2004

Access the most updated version of this article at doi: 10.1074/jbc.M403191200

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 83 references, 45 of which can be accessed free at http://www.jbc.org/content/279/28/29501.full.html#ref-list-1